SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)*

Pacira BioSciences, Inc. (Name of Issuer)

Common Stock, par value $0.001 per share (Title of Class of Securities)

(CUSIP Number)

Pedro Escudero 3350 Virginia Street, Suite 530 Miami, FL, 33133 (305) 549-5081 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/08/2026 (Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Doma Perpetual Capital Management LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) IA

SCHEDULE 13D

CUSIP No.

1	Name of reporting person DOMA1 LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) OO

SCHEDULE 13D

CUSIP No.

1	Name of reporting person DOMA Perpetual LO Equity Master Fund LP
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) PN

SCHEDULE 13D

CUSIP No.

1	Name of reporting person DOMA Perpetual Partners GP LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) OO

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Pedro Escudero
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF, PF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) IN

SCHEDULE 13D

CUSIP No.

1	Name of reporting person The John Templeton Foundation
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization TENNESSEE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) CO

SCHEDULE 13D

CUSIP No.

1	Name of reporting person DOMA2 LLC
2	Check the appropriate box if a member of a Group (See Instructions)   (a)   (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 0.00 10 Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 0.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
13	Percent of class represented by amount in Row (11) 0 %
14	Type of Reporting Person (See Instructions) OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: Pacira BioSciences, Inc.
(c)	Address of Issuer's Principal Executive Offices: 2000 Sierra Point Parkway, Suite 900, Brisbane, CALIFORNIA , 94005.
Item 1 Comment: This Amendment No. 4 ("Amendment No. 4") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on August 8, 2025, as amended by Amendment No. 1 thereto filed on November 10, 2025, Amendment No. 2 filed on January 2, 2026, and Amendment No. 3 filed on March 12, 2026 (collectively, the "Schedule 13D"), relating to shares of Common Stock, par value $0.001 per share (the "Common Shares"), of Pacira BioSciences, Inc. (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 2.	Identity and Background
(a)	Item 2(a) is hereby amended and restated in its entirety as follows: "This Schedule 13D is being filed by (i) DOMA Perpetual Capital Management LLC, a Delaware limited liability company ("DOMA"), (ii) DOMA1 LLC, a Delaware limited liability company ("Doma 1"), (iii) DOMA Perpetual LO Equity Master Fund LP, a Cayman Islands exempted limited partnership ("Doma Master Fund"), (iv) Doma Perpetual Partners GP LLC, a Delaware limited liability company ("Doma GP"), (v) Pedro Escudero, a citizen of the United States ("Mr. Escudero"), (vi) The John Templeton Foundation, a foundation organized under the laws of Tennessee ("JTF"), and (vii) DOMA2 LLC, a Delaware limited liability company ("Doma 2", and together with JTF, Mr. Escudero, Doma GP, Doma Master Fund, Doma 1 and DOMA, the "Reporting Persons"). DOMA is the investment manager of Doma Master Fund and JTF. Doma 1 is the managing member of DOMA. Doma 2 is the managing member of Doma GP. Doma GP is the general partner of Doma Master Fund. JTF is a discretionary investment management client of DOMA. Mr. Escudero is the Chief Executive Officer and Chief Investment Officer of DOMA and sole manager of Doma 1 and Doma 2."
(b)	Item 2(b) is hereby amended and restated in its entirety as follows: "The principal business address of each of DOMA, Doma 1, Doma 2, Doma GP, Doma Master Fund, and Mr. Escudero is 3350 Virginia Street, Suite 530, Miami, FL 33133. The principal business address of JTF is 300 Conshohocken State Road, Suite 500, West Conshohocken, PA 19428."
(c)	Item 2(c) is hereby amended and restated in its entirety as follows: "DOMA provides investment advisory and management services and acts as the investment manager of Doma Master Fund and JTF. Doma 1 is the managing member of DOMA. Doma 2 is the managing member of Doma GP. Doma GP is the general partner of Doma Master Fund. Doma Master Fund has been formed for the purpose of investing in securities and engaging in all related activities and transactions. JTF, via its wholly-owned investment holding company, Reliability LLC, invests in securities and engages in all related activities and transactions. Mr. Escudero is the Chief Executive Officer and Chief Investment Officer of DOMA and sole manager of Doma 1 and Doma 2."
(d)	Item 2(d) is hereby amended and restated in its entirety as follows: "During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors)."
(e)	Item 2(e) is hereby amended and restated in its entirety as follows: "During the past five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such law."
(f)	Item 2(f) is hereby amended and restated in its entirety as follows: "The information in Item 2(a) above is incorporated herein by reference."
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) is hereby amended and restated in its entirety as follows: "The percentages used in this Schedule 13D are calculated based on 39,861,886 outstanding Common Shares of the Issuer as of August 3, 2026, as provided on the cover page of the Issuer's quarterly report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 4, 2026. See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Common Shares and percentage of Common Shares beneficially owned by each of the Reporting Persons."
(b)	Item 5(b) is hereby amended and restated in its entirety as follows: "(b) Number of shares as to which each Reporting Person has: (i) sole power to vote or to direct the vote: See Item 7 on the cover page(s) hereto. (ii) shared power to vote or to direct the vote: See Item 8 on the cover page(s) hereto. (iii) sole power to dispose or to direct the disposition of: See Item 9 on the cover page(s) hereto. (iv) shared power to dispose or to direct the disposition of: See Item 10 on the cover page(s) hereto."
(c)	Item 5(c) is hereby amended and restated in its entirety as follows: "Other than as set forth on Annex A, which is incorporated herein by reference to Exhibit 99.2 hereto, there have been no transactions in the class of securities reported on that were effected by the Reporting Persons during the past sixty days or since the most recent filing of Schedule 13D, whichever is less."
(e)	Item 5(e) is hereby amended and restated in its entirety as follows: "On October 8, 2026, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Common Shares."
Item 7.	Material to be Filed as Exhibits.
	Item 7 is hereby amended and restated in its entirety as follows: "Exhibit 99.1 Joint Filing Agreement (filed herewith) Exhibit 99.2 Annex A - Recent Transactions by the Reporting Persons in the Securities of the Issuer (filed herewith)."

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Doma Perpetual Capital Management LLC

Signature: /s/ Pedro Escudero Name/Title: Pedro Escudero/Chief Executive Officer and Chief Investment Officer Date: 10/13/2026

DOMA1 LLC

Signature: /s/ Pedro Escudero Name/Title: Pedro Escudero/Manager Date: 10/13/2026

DOMA Perpetual LO Equity Master Fund LP

Signature: DOMA Perpetual Partners GP LLC Name/Title: General Partner Date: 10/13/2026

Signature: /s/ Pedro Escudero Name/Title: Pedro Escudero/Manager Date: 10/13/2026

DOMA Perpetual Partners GP LLC

Signature: /s/ Pedro Escudero Name/Title: Pedro Escudero/Manager Date: 10/13/2026

Pedro Escudero

Signature: /s/ Pedro Escudero Name/Title: Authorized Signatory Date: 10/13/2026

The John Templeton Foundation

Signature: /s/ Pedro Escudero Name/Title: Authorized Signatory Date: 10/13/2026

DOMA2 LLC

Signature: /s/ Pedro Escudero Name/Title: Pedro Escudero/Manager Date: 10/13/2026

EXHIBIT 99.1

JOINT FILING AGREEMENT

October 13, 2026

Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with the U.S. Securities and Exchange Commission (and, if such security is registered on a national securities exchange, also with the exchange), and further agrees to the filing, furnishing, and/or incorporation by reference of this agreement as an exhibit thereto. This agreement shall remain in full force and effect until revoked by any party hereto in a signed writing provided to each other party hereto, and then only with respect to such revoking party.

IN WITNESS WHEREOF, each party hereto, being duly authorized, has caused this agreement to be executed and effective as of the date first written above.

EXHIBIT 99.2

ANNEX A

RECENT TRANSACTIONS BY THE REPORTING PERSONS IN THE SECURITIES OF Pacira BioSciences, Inc.